Trial Profile

A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 22 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FE 999322 (Primary) ; FE 999324 (Primary)
Indications Ulcerative colitis
Focus Adverse reactions; Proof of concept
Sponsors Ferring Pharmaceuticals

Most Recent Events

18 Oct 2024 Status changed from recruiting to withdrawn prior to enrolment.
30 May 2024 Planned End Date changed from 15 Sep 2025 to 15 Jan 2026.
30 May 2024 Planned primary completion date changed from 15 Sep 2025 to 15 Jan 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com